{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_16484", "batch_size": 200, "batch_pos": 65, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment contains preparedness information stated neutrally.", "method": "llm_batch", "batch_id": "batch_2_19532", "batch_size": 200, "batch_pos": 43, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb paired with explicit scale or impact information.", "method": "llm_batch", "batch_id": "batch_3_7540", "batch_size": 200, "batch_pos": 178, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a question.", "method": "llm_batch", "batch_id": "batch_4_15220", "batch_size": 200, "batch_pos": 176, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports vaccine development efforts, not a calming cue about the current situation.", "method": "llm_batch", "batch_id": "batch_5_15776", "batch_size": 200, "batch_pos": 173, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "Segment does not contain a minimiser + scale contrast pattern.", "method": "llm_batch", "batch_id": "batch_6_4092", "batch_size": 200, "batch_pos": 127, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment reports actions taken, not a bare negation.", "method": "llm_batch", "batch_id": "batch_7_14456", "batch_size": 200, "batch_pos": 105, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes vaccine development/testing ('are already developing or about to test sample human vaccines') as a precautionary measure without calming keywords.", "method": "llm_batch", "batch_id": "batch_8_7732", "batch_size": 200, "batch_pos": 189, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
